Carl Zeiss Meditec AG (XSWX:AFX) Stock Price, Trades & News

Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	0.21
Equity-to-Asset	0.62
Debt-to-Equity	0.06
Debt-to-EBITDA	0.68
Interest Coverage	7.23
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.85	Distress Grey Safe
Beneish M-Score	-2.51	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	6.2
	3-Year EBITDA Growth Rate	-9.8
	3-Year EPS without NRI Growth Rate	-23.3
	3-Year FCF Growth Rate	8.6
	3-Year Book Growth Rate	2.4
	Future 3-5Y Total Revenue Growth Rate Estimate	2.93

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	89.42
	9-Day RSI	76.51
	14-Day RSI	65.51
	3-1 Month Momentum %	10.34

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.34
	Quick Ratio	1.43
	Cash Ratio	0.05
	Days Inventory	182.87
	Days Sales Outstanding	33.21
	Days Payable	65.41

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.03
	3-Year Dividend Growth Rate	-12.6
	Forward Dividend Yield %	2.03
	5-Year Yield-on-Cost %	2.97
	3-Year Average Share Buyback Ratio	0.7
	Shareholder Yield %	2.31

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	52.18
	Operating Margin %	8.91
	Net Margin %	5.47
	EBITDA Margin %	8.87
	FCF Margin %	11.44
	OCF Margin %	11.44
	ROE %	5.8
	ROA %	3.52
	ROIC %	4.58
	3-Year ROIIC %	-23.21
	ROC (Joel Greenblatt) %	32.42
	ROCE %	6.88
	Years of Profitability over Past 10-Year	10
	Moat Score	7
	Tariff Resilience Score	5

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	19.66
	Forward PE Ratio	16.85
	PE Ratio without NRI	19.66
	Shiller PE Ratio	11.8
	PEG Ratio	4.68
	PS Ratio	1.05
	PB Ratio	1.11
	Price-to-Tangible-Book	4.87
	Price-to-Free-Cash-Flow	9.28
	Price-to-Operating-Cash-Flow	9.28
	EV-to-EBIT	12.65
	EV-to-Forward-EBIT	12.44
	EV-to-EBITDA	12.65
	EV-to-Forward-EBITDA	8.21
	EV-to-Revenue	1.12
	EV-to-Forward-Revenue	1.08
	EV-to-FCF	9.79
	Price-to-GF-Value	0.37
	Price-to-Projected-FCF	0.97
	Price-to-DCF (Earnings Based)	1.27
	Price-to-DCF (FCF Based)	0.73
	Price-to-Median-PS-Value	0.23
	Price-to-Graham-Number	1.9
	Earnings Yield (Greenblatt) %	7.91
	FCF Yield %	10.72
	Forward Rate of Return (Yacktman) %	3.81

GF Value™: CHF67.74

XSWX:AFX

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with AFX. Try a 7-Day Free Trial to check it out.

Carl Zeiss Meditec AG Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Carl Zeiss Meditec AG Stock Events

Financials Calendars

Event	Date	Price (CHF)
Annual report for 2026	2026-12-11	In 170 days
Fourth quarter earnings conference call for 2026	2026-12-11	In 170 days
Fourth quarter earnings results for 2026	2026-12-11	In 170 days
Third quarter earnings conference call for 2026	2026-08-06	In 43 days
Third quarter earnings results for 2026	2026-08-06	In 43 days
Second quarter earnings conference call for 2026	2026-05-12	24.10 (+0.00%)
Second quarter earnings results for 2026	2026-05-12	24.10 (+0.00%)
EUR 0.550000 Cash Dividend	2026-03-27	21.54 (+0.00%)
General meeting for 2025	2026-03-26 10:00	21.54 (+0.00%)
First quarter earnings conference call for 2026	2026-02-12	25.58 (+0.00%)

Show

Entries

Press Release

	Subject	Date
	ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing	2026-06-18
	ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units	2026-06-17
	ZEISS announces successful early implantations of the AT LUCIA toric 721P intraocular lens	2026-06-11
	ZEISS expands ophthalmic surgical workflows in Mexico with COFEPRIS approval for ARTEVO 850 and MICOR 700	2026-05-13
	ZEISS advances connected cataract and refractive workflows with new digital, AI and surgical innovations at ASCRS	2026-04-02
	ZEISS expands ophthalmic workflow portfolio in Canada with enhanced diagnostic, visualization and therapeutic solutions for precision eye care	2026-03-24
	ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options	2026-02-23
	ZEISS announces NMPA approval in China for powerful ophthalmic microscopes enhancing surgical visualization	2026-02-02
	ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization	2025-10-07
	ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones	2025-09-02

10/Page

Articles on Carl Zeiss Meditec AG

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.